Ketogenic diet: an alternative treatment for refractory epilepsy in children

P Kankirawatana1, P Jirapinyo, S Kankirawatana

  • 1Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Insights

The ketogenic diet effectively reduced seizures in children with refractory epilepsy in Thailand. This treatment is feasible and cost-effective, even with limited resources.

Area of Science:

  • Neurology
  • Dietary Therapy
  • Epilepsy Management

Background:

  • Refractory epilepsy poses a significant challenge in Thailand.
  • The ketogenic diet is a recognized treatment for epilepsy but its implementation in resource-limited settings requires evaluation.

Purpose of the Study:

  • To establish the first ketogenic diet program for refractory epilepsy in Thailand.
  • To assess the feasibility and efficacy of the ketogenic diet in a Thai pediatric population.

Main Methods:

  • A prospective open trial involving 35 children with refractory epilepsy.
  • Utilized a modified classic "4:1" ketogenic diet formula, allowing for locally available fatty foods like coconut milk.
  • Close supervision, parent education, and regular monitoring of seizure outcomes, side effects, and urine ketones.

Main Results:

  • Significant seizure reduction achieved: over 60% of patients experienced 90% seizure reduction at 12 months.
  • High efficacy rates observed at various time points: 62.5% at 1 month, 68.18% at 3 months, 75% at 6 months, and 66.67% at 12 months.
  • A decrease in the number of antiepileptic drugs (AEDs) used per patient was noted.

Conclusions:

  • The ketogenic diet is a viable management option for refractory epilepsy in Thailand.
  • Implementation is feasible even in developing countries with limited resources.
  • This dietary therapy may offer a cost-effective alternative to expensive new antiepileptic drugs.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.